Can Platinib cure liver cancer? Can it be cured?

According to the current published research data, Pralsetinib (Pralsetinib) is not a standard first-line or second-line therapy for the treatment of liver cancer. The main indications for Platinib are certain types of non-small cell lung cancer (especially NSCLC with RET fusion gene mutations) and certain types of thyroid cancer (TC), especially Anaplastic Thyroid Cancer (ATC) with RET fusion positivity. However, there is insufficient clinical data to support the efficacy of platinib in the treatment of liver cancer.

As a malignant tumor, liver cancer has a complex and difficult treatment process. Regarding the treatment of liver cancer, currently recognized treatment methods mainly include surgical resection, interventional therapy (such as radiofrequency ablation, microwave ablation, transcatheter arterial chemoembolization, etc.), liver transplantation, and targeted drugs and immunotherapy for different pathological types, such as sorafenib (Sorafenib) for the first-line treatment of advanced hepatocellular carcinoma, Lenvatinib and bevacizumab combined with chemotherapy for the first-line treatment of advanced hepatocellular carcinoma, and PD-1/PD-L1 antibodies such as pembrolizumab ( Immune checkpoint inhibitors such as Pembrolizumab and Nivolumab in hepatocellular carcinoma and other types of liver cancer.

As for whether platinib can treat liver cancer and its curative effect, there is currently insufficient clinical evidence to support this view. Although theoretically, RET inhibitors like platinib may play a role in a small number of rare liver cancer subtypes carrying RET fusion gene mutations, they are not widely used in clinical liver cancer treatment, and their efficacy data are still limited.